Trials / Completed
CompletedNCT03722147
A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma
A Single-arm, Multicenter, Open-label, Phase I/II Study of AK105 as Monotherapy in Relapsed or Refractory Classic Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, multicenter, phase I/II study to evaluate efficacy and safety of AK105 in patients with relapsed or refractory classic Hodgkin lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AK105 | AK105 200 mg intravenously (IV) every-2-weeks (Q2W) |
Timeline
- Start date
- 2018-08-13
- Primary completion
- 2020-01-10
- Completion
- 2021-12-31
- First posted
- 2018-10-26
- Last updated
- 2024-04-03
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03722147. Inclusion in this directory is not an endorsement.